CurrentPremera BluecrossPolicy 7.01.522

Gastric Electrical Stimulation

Defines medical necessity criteria, documentation, coding, and investigational exclusions for implantable gastric electrical stimulation (GES) primarily for chronic, intractable nausea and vomiting due to gastroparesis and states GES is investigational for obesity and other indications.

Policy Summary

PayerPremera Bluecross

PolicyGastric Electrical Stimulation

Policy CodePolicy 7.01.522

Change TypeAnnual reviewcoding updates

Effective DateMay 1, 2026

Next Review Date

Key ActionSubmit medical records demonstrating all medical necessity criteria are met, including gastric emptying scintigraphy, trials/intolerance of prokinetic and antiemetic medications, and nutritional status indicating likely need for TPN.

SourceLink

POLICY UPDATE CHANGES

Annual Review, approved April 13, 2026; policy updated with literature review through December 23, 2025; reference added; policy statements unchanged.

04/01/26 coding update added CPT code 64590 to support policy criteria.

01/01/26 coding update added HCPCS code C1607; subsequently removed 03/01/26.

1Medically Necessary Indication (gastroparesis diabetic or idiopathic)

1Investigational Indication (obesity)

8Key CPT/HCPCS codes listed

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Policy 7.01.522 (payer: Premera) is a CURRENT coverage criteria document for Gastric Electrical Stimulation (GES) that takes a mixed coverage stance: GES is supported as medically necessary for chronic, intractable nausea and vomiting due to diabetic or idiopathic gastroparesis when specific criteria are met, and investigational for obesity and other indications. Status effective date is May 1, 2026 with last review Apr. 13, 2026.

Thresholds / Dates

Gastric emptying documentationSignificantly delayed gastric emptying as documented by standard scintigraphic imaging (gastric emptying scan)

Nutritional status thresholdIndividual's nutritional status sufficiently low so that total parenteral nutrition (TPN) is likely to become medically necessary

Effective dateMay 1, 2026

Last review dateApr. 13, 2026

Medical Necessity Criteria

Medical Necessity - Gastric electrical stimulation (GES)

Gastric electrical stimulation may be considered medically necessary when ALL of the following criteria are met:

Symptom criterion: Chronic, intractable nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology
Gastric emptying documentation: Significantly delayed gastric emptying as documented by standard scintigraphic imaging (gastric emptying scan) of solid foodDocumented significantly delayed gastric emptying on standard scintigraphic imaging (gastric emptying scan)
Medication failure/intolerance: The individual is refractory or intolerant of prokinetic (antireflux) medications and antiemetic medications
Nutritional status threshold: The individual's nutritional status is sufficiently low so that total parenteral nutrition is likely to become medically necessaryNutritional status low enough that total parenteral nutrition (TPN) is likely to become medically necessary

Investigational / Not Medically Necessary

GES is considered investigational (unproven) for the following:

Obesity indication: GES for the treatment of obesity
SHAPE trial did not show significant improvement in weight loss compared with sham
Other indications: GES for all other indications (other than chronic, intractable nausea and vomiting secondary to diabetic or idiopathic gastroparesis meeting above criteria)

Coding

Covered / Supported CPT codesCPTCovered

43647	Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum.
43648	Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum.
43881	Implantation or replacement of gastric neurostimulator electrodes, antrum, open.
43882	Revision or removal of gastric neurostimulator electrodes, antrum, open.
64590	Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.

Covered / Supported HCPCS / Implantable device codesHCPCSCovered

C1767	Generator, neurostimulator (implantable), nonrechargeable.
C1778	Lead, neurostimulator (implantable).
L8679	Implantable neurostimulator, pulse generator, any type.
L8680	Implantable neurostimulator electrode, each.
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension.
L8686	Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension.
L8687	Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension.
L8688	Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension.

Provider Actions

Documentation Required

Submit medical records demonstrating criteria

Medical records submitted for review must document that ALL medical necessity criteria are met for GES. Records should clearly demonstrate the patient meets the policy's required clinical findings, prior treatment trials or intolerances, and nutritional status thresholds.

Significantly delayed gastric emptying as documented by standard scintigraphic imaging (gastric emptying scan).
Refractory to or intolerant of prokinetic (antireflux) medications and antiemetic medications (document trials and responses/intolerance).
Nutritional status sufficiently low that total parenteral nutrition (TPN) is likely to become medically necessary.

Billing Rule

Use specified CPT/HCPCS codes

Report the applicable CPT and HCPCS codes listed in the policy when billing for implantation, revision/removal, pulse generator insertion/replacement, and device supplies for GES services.

43647
43648
43881
43882
64590
C1767
C1778
L8679
L8680
L8685
L8686
L8687
L8688

Background and Evidence

GES (Enterra Therapy System) is an implantable pulse generator connected to intramuscular gastric leads, implanted laparoscopically or via laparotomy, intended to reduce nausea and vomiting in medically refractory gastroparesis. The Enterra system was approved by the FDA under a Humanitarian Device Exemption (HDE). The evidence base includes randomized controlled trials, nonrandomized studies, systematic reviews and meta-analyses with inconsistent results; some analyses show limited or no significant benefit and others show heterogeneous, inconsistent improvements. Given the limited quality and mixed results, GES may be considered when severe symptoms and compromised nutritional status make total parenteral nutrition (TPN) likely.

Study / Source	Summary
2017 meta-analysis
Did not find a significant benefit of GES on severity of gastroparesis symptoms; improved symptoms reported regardless of device activation suggesting placebo effects.
2022 meta-analysis
Found some improvements but interpretation limited by inconsistent outcomes across timepoints and high heterogeneity (I2 = 70%); study populations not always representative of intended population.
Hayes 2016 report
Rated evidence poor to fair; GES may improve symptoms, gastric emptying, and decrease need for nutritional support in some individuals; device removal rate 7%-12%.
SHAPE trial (obesity)
Randomized trial did not show significant improvement in weight loss compared with sham; GES considered investigational for obesity.

Definitions: GES — gastric electrical stimulation, an implantable device that delivers electrical pulses to the stomach to reduce nausea and vomiting; TPN — total parenteral nutrition; HDE — Humanitarian Device Exemption, the FDA regulatory pathway under which the Enterra Therapy System was approved.

Revision History

Apr 13, 2026annual_reviewLatest

Annual Review, approved April 13, 2026; policy updated with literature review through December 23, 2025; reference added; policy statements unchanged.

04/01/26coding_update

04/01/26 coding update added CPT code 64590 to support policy criteria.

03/01/26coding_update

03/01/26 coding update removed HCPCS code C1607; C1607 had been added effective 01/01/26 and subsequently removed.

01/01/26coding_update

01/01/26 coding update added HCPCS code C1607 (later removed 03/01/26).